CompanyAwarded grant from Maryland Stem Cell Research Fund.
MIAMI, Fla., May 22, 2017 -- Longeveron announced receiving a $750,000 grant from the Maryland Stem Cell Research Fund (MSCRF) to continue its stem cell research.
Longeveron will partner with the University of Maryland and Johns Hopkins University to conduct a clinical trial for hypoplastic left heart syndrome (HLHS), a rare and often fatal condition in infants caused by an underdeveloped heart.
Sunjay Kaushal of the University of Maryland said the HLHS trial "may be a game changing procedure" to improve ventricular performance for, and possibly increase the lifespan of, HLHS babies.
The MSCRF was established by the Governor and the Maryland General Assembly through the Maryland Stem Cell Research Act of 2006 to accelerate research using human stem cells and advance medical treatmen.
Contact: http://www.longeveron com
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Grants & Contracts|
|Publication:||Stem Cell Lab World|
|Date:||May 29, 2017|
|Previous Article:||Testing the safety of stem cell therapy for early menopause.|
|Next Article:||Texas about to lower its standards for approving stem cell other therapies.|